Addex Therapeutics Ltd ADXN
At closeNov 4, 2026, 8:58 AM EST
Pre-market · Nov 4, 8:58 AM ET
- YTD
- -61.08%
- 1 year
- -68.03%
- Market cap
- 5.27M
- Revenue (ttm)
- 863.23K
- Profit margin
- 500.16%
- EPS (ttm)
- -7.56
- Shares out
- 1.07M
- Forward P/E
- -159.83
- YTD return
- -61.08%
- 1-year return
- -68.03%
- Volume
- 1.25K
- Avg volume
- 139.26K
- Open
- 3.01
- Previous close
- 2.92
- Day's range
- 3.01 – 3.01
- 52-week range
- 2.56 – 10.43
- Beta
- 1.87
- Price target
- 30.00 (+898.3%)
- Earnings date
- Jun 6, 2024
3M -2.68 (-47.10%)
Key statistics
- Enterprise value
- 793.44M
- PEG ratio
- 0.00
- Price / sales
- 10.07
- Price / book
- 887.93
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -81.80%
- Free cash flow
- -5.81M
- Total cash
- 3.79M
- Total debt
- 32.18K
- Return on equity
- -126.29%
- Short % of float
- 0.41%
- 50-day average
- 9.13
- 200-day average
- 10.24
Analyst view
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Jun 6, 2024
Expected Jun 6, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jun 6, 2024 | Mar 1, 2024 | 0.00 | -1.37 | — | — |
| Jun 6, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Apr 18, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
| Apr 18, 2024 | Dec 1, 2023 | 0.00 | -4.06 | — | — |
| Nov 29, 2023 | Sep 1, 2023 | -4.00 | — | — | — |
| Nov 29, 2023 | Sep 1, 2023 | -4.00 | -4.07 | -0.07 | -1.75% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 31, 2024 | HC Wainwright & Co. | up | Neutral | Buy |
About Addex Therapeutics Ltd
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Switzerland
- Website
- addextherapeutics.com
News
ADDEX INCREASES ISSUED SHARE CAPITAL TO CREATE TREASURY SHARES 
Reviewing Addex Therapeutics (NASDAQ:ADXN) & Clene (NASDAQ:CLNN) 
12 Health Care Stocks Moving In Thursday's After-Market Session - 12 Health Care Stocks Moving In Thursday's Pre-Market Session
Addex (NASDAQ: ADXN) spin-out Neurosterix clears Phase 1, plans next stage 
Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for Schizophrenia 
Addex Therapeutics Announces Executive Management Changes 
What Addex Therapeutics (ADXN) Said on Its Q2 Earnings Call 
12 Health Care Stocks Moving In Monday's After-Market Session 
Addex Therapeutics Ltd (ADXN) Q2 2026 Earnings Call Transcript
Your note
Sign in to keep a note on ADXN — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Adar1 Capital Management, LLC | 0.07% | 1,000 | 7.99K | Sep 29, 2024 |
| Morgan Stanley | 0.02% | 353 | 2.82K | Sep 29, 2024 |
| Rhumbline Advisers | 0.00% | 35 | 279 | Sep 29, 2024 |